Inventor · disambiguated record
Mitchell Ho
Also filed as: HO MITCHELL
20 granted patents·10 pending applications·194 citations·filing 2004–2024
94Inventor score
Top patents by PatentIndex Score
30 records- 0194US9803022B2Mesothelin domain-specific monoclonal antibodies and use thereofUS HEALTH·Filed 2016·Granted Oct 31, 2017·15 cites·28 claims
- 0294US9416190B2Mesothelin antibodies and methods for eliciting potent antitumor activityUS HEALTH·Filed 2013·Granted Aug 16, 2016·31 cites·28 claims
- 0393US8460660B2Anti-mesothelin antibodiesHO MITCHELL·Filed 2010·Granted Jun 11, 2013·19 cites·19 claims
- 0492US9409992B2Mesothelin domain-specific monoclonal antibodies and use thereofUS HEALTH·Filed 2013·Granted Aug 9, 2016·16 cites·27 claims
- 0591US9394364B2Human monoclonal antibodies specific for glypican-3 and use thereofUS HEALTH·Filed 2015·Granted Jul 19, 2016·14 cites·27 claims
- 0691US7982011B2Mutated anti-cd22 antibodies and immunoconjugatesUS HEALTH·Filed 2004·Granted Jul 19, 2011·57 cites·40 claims
- 0790US9206257B2Human monoclonal antibodies specific for glypican-3 and use thereofHO MITCHELL·Filed 2012·Granted Dec 8, 2015·8 cites·22 claims
- 0889US11066479B2Monoclonal antibodies targeting glypican-2 (GPC2) and use thereofUS HEALTH·Filed 2017·Granted Jul 20, 2021·4 cites·45 claims
- 0989US9409994B2High-affinity monoclonal antibodies to glypican-3 and use thereofUS HEALTH·Filed 2013·Granted Aug 9, 2016·18 cites·33 claims
- 1085US8623828B2Blocking mesothelin peptide fragmentsHO MITCHELL·Filed 2008·Granted Jan 7, 2014·8 cites·27 claims
- 1183US12012463B2High affinity monoclonal antibodies targeting glypican-2 and uses thereofUS HEALTH·Filed 2019·Granted Jun 18, 2024·2 cites·45 claims
- 1281US12492262B2High affinity monoclonal antibodies targeting glypican-2 and uses thereofUS HEALTH·Filed 2024·Granted Dec 9, 2025·0 cites·40 claims
- 1376US2023406953A1Chimeric antigen receptors targeting tumor antigensUS HEALTH·Filed 2023·Application pending·0 cites
- 1475US11390683B2Anti-mesothelin polypeptides and proteinsUS HEALTH·Filed 2018·Granted Jul 19, 2022·1 cites·19 claims
- 1573US11795235B2Immunotoxins with albumin binding domainUS HEALTH·Filed 2018·Granted Oct 24, 2023·1 cites·18 claims
- 1671US12215164B2Immunotoxins with albumin binding domainUS HEALTH·Filed 2023·Granted Feb 4, 2025·0 cites·23 claims
- 1769US10640571B2Human monoclonal antibodies specific for glypican-3 and use thereofUS HEALTH·Filed 2017·Granted May 5, 2020·0 cites·21 claims
- 1867US2025281538A1Compositions targeting gpc2 and gpc3 and their use for treating solid tumorsUS HEALTH·Filed 2023·Application pending·0 cites
- 1964US9932406B2Human monoclonal antibodies specific for glypican-3 and use thereofUS HEALTH·Filed 2016·Granted Apr 3, 2018·0 cites·19 claims
- 2062US11802163B2Chimeric antigen receptors targeting glypican-3 or mesothelinUS HEALTH·Filed 2018·Granted Oct 31, 2023·0 cites·36 claims
- 2162US2025017962A1Igg4 hinge-containing chimeric antigen receptors targeting glypican-3 (gpc3) and use thereofUS HEALTH·Filed 2022·Application pending·0 cites
- 2260US2025144214A1Cd28 hinge and transmembrane containing chimeric antigen receptors targeting gpc2 and use thereofUS HEALTH·Filed 2023·Application pending·0 cites
- 2360US2024417446A1Single domain antibodies targeting the s2 subunit of sars-cov-2 spike proteinUS HEALTH·Filed 2022·Application pending·0 cites
- 2457US2024218055A1Lassa virus-specific nanobodies and methods of their useUS HEALTH·Filed 2022·Application pending·0 cites
- 2556US2025018040A1Anti-mesothelin polypeptides, proteins, and chimeric antigen receptorsTHE US SECRETARY DEPARTMENT OF HEALTH AND HUMAN SERVIC·Filed 2022·Application pending·0 cites
- 2655US12180296B2Cross species single domain antibodies targeting mesothelin for treating solid tumorsUS HEALTH·Filed 2020·Granted Dec 31, 2024·0 cites·40 claims
- 2755US2024270851A1Cross species single domain antibodies targeting pd-l1 for treating solid tumorsUS HEALTH·Filed 2022·Application pending·0 cites
- 2850US2023340146A1Igg4 hinge-containing chimeric antigen receptors targeting glypican-1 (gpc1) for treating solid tumorsUS HEALTH·Filed 2021·Application pending·0 cites
- 2949US12122843B2High affinity monoclonal antibodies targeting glypican-1 and methods of useUS HEALTH·Filed 2020·Granted Oct 22, 2024·0 cites·40 claims
- 3048US2023391852A1Single domain antibodies targeting sars coronavirus spike protein and uses thereofUS HEALTH·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mitchell Ho files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →